NASDAQ:CGEM Cullinan Oncology - CGEM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cullinan Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.91 +0.33 (+2.85%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$11.51▼$11.9250-Day Range$9.72▼$13.4152-Week Range$7.30▼$15.89Volume395,840 shsAverage Volume152,229 shsMarket Capitalization$543.22 millionP/E Ratio5.36Dividend YieldN/APrice Target$50.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cullinan Oncology MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside319.8% Upside$50.00 Price TargetShort InterestBearish7.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$53,200 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.64) to ($2.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector651st out of 1,030 stocksBiological Products, Except Diagnostic Industry98th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingCullinan Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.00, Cullinan Oncology has a forecasted upside of 319.8% from its current price of $11.91.Amount of Analyst CoverageCullinan Oncology has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.22% of the float of Cullinan Oncology has been sold short.Short Interest Ratio / Days to CoverCullinan Oncology has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cullinan Oncology has recently decreased by 1.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Oncology does not currently pay a dividend.Dividend GrowthCullinan Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Cullinan Oncology this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for CGEM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,200.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Cullinan Oncology is held by insiders.Percentage Held by Institutions80.85% of the stock of Cullinan Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Cullinan Oncology are expected to grow in the coming year, from ($3.64) to ($2.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Oncology is 5.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Oncology is 5.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.37.Price to Book Value per Share RatioCullinan Oncology has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cullinan Oncology (NASDAQ:CGEM) StockCullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Stock News HeadlinesFebruary 2, 2023 | finance.yahoo.comCullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma ConferenceJanuary 27, 2023 | americanbankingnews.comComparing X4 Pharmaceuticals (NASDAQ:XFOR) and Cullinan Oncology (NASDAQ:CGEM)February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 25, 2023 | seekingalpha.comCGEM Cullinan Oncology, Inc.January 24, 2023 | finance.yahoo.comCullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin LymphomaNovember 14, 2022 | finance.yahoo.comCullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comCullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of DirectorsOctober 25, 2022 | finance.yahoo.comCullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619February 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.September 4, 2022 | reuters.comCullinan Oncology IncAugust 16, 2022 | finance.yahoo.comCullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal OfficerAugust 13, 2022 | seekingalpha.comCullinan Oncology (CGEM) Investor Presentation - SlideshowAugust 10, 2022 | finance.yahoo.comCullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsAugust 1, 2022 | finance.yahoo.comCullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth ConferenceJuly 5, 2022 | finance.yahoo.comCullinan Oncology to Participate in William Blair Biotech Focus ConferenceJune 6, 2022 | seekingalpha.comCullinan Oncology discloses $8.3M share buy by insiderJune 2, 2022 | seekingalpha.comCullinan Oncology grants stock options to employeesMay 31, 2022 | finance.yahoo.comCullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual MeetingMay 19, 2022 | finance.yahoo.comCullinan Oncology to Present at H.C. Wainwright Global Investment ConferenceMay 17, 2022 | benzinga.comShort Volatility Alert: Cullinan OncologyMay 16, 2022 | investing.comCullinan Oncology Reports Q1 Net Loss of $12.9MMay 13, 2022 | nasdaq.comNotable Thursday Option Activity: ROKU, CGEM, CPRIMay 12, 2022 | finance.yahoo.comCullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan PearlMay 8, 2022 | finance.yahoo.comCompanies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In GrowthApril 27, 2022 | finance.yahoo.comCullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual MeetingApril 5, 2022 | finance.yahoo.comCullinan Oncology to Participate in Upcoming Virtual Healthcare ConferencesApril 4, 2022 | finance.yahoo.comCullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Forecast$50.00 High Stock Price Forecast$50.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+319.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.22 Trailing P/E Ratio5.36 Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,570,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.66% Return on Assets-31.74% Debt Debt-to-Equity RatioN/A Current Ratio21.47 Quick Ratio21.47 Sales & Book Value Annual Sales$18.94 million Price / Sales28.68 Cash FlowN/A Price / Cash FlowN/A Book Value$9.74 per share Price / Book1.22Miscellaneous Outstanding Shares45,610,000Free Float42,191,000Market Cap$543.22 million OptionableNot Optionable Beta0.13 Key ExecutivesMr. Nadim Ahmed (Age 54)Pres, CEO & Director Comp: $824kMr. Jeffrey Trigilio (Age 37)CFO & Treasurer Comp: $634.5kDr. Patrick A. Baeuerle Ph.D. (Age 64)Chief Scientific Officer Comp: $702.8kMs. Jacquelyn L. Sumer J.D. (Age 44)Chief Legal Officer, Chief Compliance Officer & Corp. Sec. Ms. Rose WeldonVP of CommunicationsMr. Steve AndreChief HR OfficerDr. Corinne Savill Ph.D. (Age 63)Chief Bus. Officer Dr. Jennifer Michaelson Ph.D. (Age 54)Chief Devel. Officer Ms. Kerry WhalenSr. Director of Preclinical & Early Devel.Dr. Jeffrey Jones M.B.A. (Age 51)M.D., M.P.H., Chief Medical Officer More ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEMesoblastNASDAQ:MESONanoString TechnologiesNASDAQ:NSTGCompass TherapeuticsNASDAQ:CMPXAlloVirNASDAQ:ALVRView All CompetitorsInsiders & InstitutionsNisa Investment Advisors LLCSold 3,341 shares on 2/2/2023Ownership: 0.030%SG Americas Securities LLCBought 949 shares on 2/2/2023Ownership: 0.027%Assenagon Asset Management S.A.Bought 83,010 shares on 1/12/2023Ownership: 0.182%Bank of New York Mellon CorpBought 13,574 shares on 12/8/2022Ownership: 0.232%Birchview Capital LPSold 20,000 shares on 11/28/2022Ownership: 0.055%View All Insider TransactionsView All Institutional Transactions CGEM Stock - Frequently Asked Questions Should I buy or sell Cullinan Oncology stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks. What is Cullinan Oncology's stock price forecast for 2023? 3 brokers have issued 12 month target prices for Cullinan Oncology's stock. Their CGEM share price forecasts range from $50.00 to $50.00. On average, they predict the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 319.8% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts. How have CGEM shares performed in 2023? Cullinan Oncology's stock was trading at $10.55 at the beginning of the year. Since then, CGEM stock has increased by 12.9% and is now trading at $11.91. View the best growth stocks for 2023 here. When is Cullinan Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our CGEM earnings forecast. How were Cullinan Oncology's earnings last quarter? Cullinan Oncology, Inc. (NASDAQ:CGEM) released its earnings results on Monday, November, 14th. The company reported ($0.54) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.43. When did Cullinan Oncology IPO? (CGEM) raised $149 million in an initial public offering on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. What is Cullinan Oncology's stock symbol? Cullinan Oncology trades on the NASDAQ under the ticker symbol "CGEM." Who are Cullinan Oncology's major shareholders? Cullinan Oncology's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.18%), Nisa Investment Advisors LLC (0.03%), SG Americas Securities LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2. View institutional ownership trends. How do I buy shares of Cullinan Oncology? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cullinan Oncology's stock price today? One share of CGEM stock can currently be purchased for approximately $11.91. How much money does Cullinan Oncology make? Cullinan Oncology (NASDAQ:CGEM) has a market capitalization of $543.22 million and generates $18.94 million in revenue each year. The company earns $-65,570,000.00 in net income (profit) each year or $2.22 on an earnings per share basis. How can I contact Cullinan Oncology? The official website for the company is www.cullinanoncology.com. The company can be reached via phone at 617-410-4650 or via email at investors@cullinanoncology.com. This page (NASDAQ:CGEM) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.